Vor Biopharma (NYSE:VOR) Trading Down 5.3%

Vor Biopharma Inc. (NYSE:VOR)’s share price dropped 5.3% during mid-day trading on Monday . The company traded as low as $1.76 and last traded at $1.80. Approximately 295,895 shares were traded during trading, a decline of 1% from the average daily volume of 299,641 shares. The stock had previously closed at $1.90.

Analyst Ratings Changes

VOR has been the topic of a number of research reports. Oppenheimer restated an “outperform” rating and set a $15.00 target price (down from $17.00) on shares of Vor Biopharma in a research report on Thursday, March 21st. JMP Securities reiterated a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a research report on Friday, March 22nd. Stifel Nicolaus cut their price target on shares of Vor Biopharma from $15.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, March 21st. Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Vor Biopharma in a research report on Thursday, March 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a research report on Thursday, March 21st. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $13.50.

Vor Biopharma Stock Performance

The firm has a market capitalization of $122.80 million, a price-to-earnings ratio of -1.02 and a beta of -0.36. The business’s 50-day moving average is $2.09 and its two-hundred day moving average is $2.12.

Vor Biopharma (NYSE:VOR) last announced its earnings results on Wednesday, March 20th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.10. Analysts forecast that Vor Biopharma Inc. will post -1.34 EPS for the current year.

Institutional Trading of Vor Biopharma

Several hedge funds have recently bought and sold shares of the stock. Laurion Capital Management LP grew its stake in shares of Vor Biopharma by 271.3% during the 4th quarter. Laurion Capital Management LP now owns 3,182,889 shares of the company’s stock worth $21,166,000 after acquiring an additional 2,325,581 shares in the last quarter. BlackRock Inc. grew its stake in shares of Vor Biopharma by 362.9% in the second quarter. BlackRock Inc. now owns 2,164,732 shares of the company’s stock valued at $6,689,000 after buying an additional 1,697,134 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Vor Biopharma by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 1,743,463 shares of the company’s stock valued at $3,923,000 after buying an additional 27,017 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Vor Biopharma by 128.6% in the second quarter. Geode Capital Management LLC now owns 722,405 shares of the company’s stock valued at $2,232,000 after buying an additional 406,458 shares in the last quarter. Finally, State Street Corp raised its position in shares of Vor Biopharma by 1,131.2% in the second quarter. State Street Corp now owns 629,286 shares of the company’s stock valued at $1,944,000 after purchasing an additional 578,173 shares during the period. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.